Clinical Trials Browser

OTHER × Interventional × MLN 8237 × Clear all

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02114229 2026-03-17

SJATRT

Phase 2 Active not recruiting

Rhabdoid Tumor

NCT02860000 2026-02-27

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Phase 2 Completed

96 enrolled 34 charts

Breast Neoplasms

NCT04555837 2025-05-20

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

Phase 1/2 Completed

24 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

9 enrolled 9 charts

Prostatic Neoplasms

NCT02186509 2025-04-30

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

Phase 1 Completed

17 enrolled 11 charts

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT04085315 2024-06-10

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Phase 1 Recruiting

Lung Cancer Metastatic

NCT02293005 2022-10-04

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Phase 2 Completed

28 enrolled 11 charts

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

NCT01924260 2022-08-02

Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02719691 2022-07-25

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

Phase 1 Completed

47 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02530619 2021-05-26

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

Phase NA Unknown

26 enrolled 10 charts

MyeloidOther hematologic neoplasm

Leukemia, Megakaryoblastic, Acute, Primary Myelofibrosis

NCT02560025 2020-05-05

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

Phase 2 Completed

42 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01601535 2019-07-31

Study of MLN8237 in Combination With Irinotecan and Temozolomide

Phase 1/2 Completed

54 enrolled 25 charts

Neuroblastoma

NCT01639911 2019-07-22

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Phase 1 Completed

BreastCNSDermatologicGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Melanoma, Central Nervous System Neoplasms

NCT02109328 2019-04-11

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01923337 2019-01-04

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02219789 2018-10-03

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Phase 1 Completed

Breast Neoplasms

NCT01540682 2018-08-29

MLN8237 in Head and Neck Cancer

Phase 1 Completed

Head and Neck Neoplasms, Laryngeal Diseases

NCT02780011 2018-07-27

AD3LE

Phase 1 Withdrawn

Recurrence

NCT01812005 2018-06-06

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 2 Terminated

14 enrolled 11 charts

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01471964 2018-05-17

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Phase 1/2 Terminated

Non-small Cell Lung Cancer Metastatic

NCT01799278 2018-01-23

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Phase 2 Completed

60 enrolled 10 charts

Prostatic Neoplasms

NCT01677559 2018-01-11

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Phase 1 Completed

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT02700022 2017-11-20

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas

Phase 1 Terminated

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02812056 2017-03-27

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Phase 1 Withdrawn

Malignant Neoplasms of Digestive Organs

NCT01779843 2017-02-17

Alisertib for Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01034553 2016-05-25

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

26 enrolled 7 charts

Multiple Myeloma